Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865096 | 0.89 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL15870144 | 0.86 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL15865417 | 0.84 | LRRK2 (0.73) | LRRK2 | |
| SCHEMBL15864649 | 0.83 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL15864797 | 0.81 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL15864509 | 0.81 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL15865251 | 0.80 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL15865136 | 0.80 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL15865010 | 0.80 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL15870205 | 0.78 | LRRK2 (1.00) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941425-B1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-07-12 | — | — | EP | claimed |
| CN-104903311-B | Aminopyridine derived compounds as LRRK2 inhibitors | H.隆德贝克有限公司 | 2016-11-09 | — | — | CN | claimed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | claimed |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | H. LUNDBECK A/S (DK) | 2016-06-30 | — | — | US | claimed |
| US-9321748-B2 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-04-26 | — | — | US | claimed |
| US-20150336942-A1 | Aminopyridine derived compounds as LRRK2 inhibitors | VERNALIS (R&D) LTD. (GB) | 2015-11-26 | — | — | US | claimed |
| EP-2941425-A1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2015-11-11 | — | — | EP | claimed |
| WO-2014106612-A1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | WO | claimed |
| EP-2941425-B1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-07-12 | — | — | EP | disclosed |
| EP-2941425-B1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-07-12 | — | — | EP | disclosed |
| CN-104903311-B | Aminopyridine derived compounds as LRRK2 inhibitors | H.隆德贝克有限公司 | 2016-11-09 | — | — | CN | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-9321748-B2 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-04-26 | — | — | US | disclosed |
| US-20150336942-A1 | Aminopyridine derived compounds as LRRK2 inhibitors | VERNALIS (R&D) LTD. (GB) | 2015-11-26 | — | — | US | disclosed |
| US-20150336942-A1 | Aminopyridine derived compounds as LRRK2 inhibitors | VERNALIS (R&D) LTD. (GB) | 2015-11-26 | — | — | US | disclosed |
| US-20150336942-A1 | Aminopyridine derived compounds as LRRK2 inhibitors | VERNALIS (R&D) LTD. (GB) | 2015-11-26 | — | — | US | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014106612-A1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336942-A1 | Aminopyridine derived compounds as LRRK2 inhibitors | LRRK2, PARK7, SNCA | LRRK2 1/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | LRRK2 3707/4885 |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | LRRK2, PARK7, SNCA | LRRK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.